Put companies on watchlist
bonyf NV
ISIN: BE6333353298
WKN: A3D1EU
Curious about what AI knows about Bonyf? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

bonyf NV · ISIN: BE6333353298 · EQS - Company News (9 News)
Country: Belgium · Primary market: Belgium · EQS NID: 2113236
08 April 2025 10:17AM

bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream


bonyf NV / Key word(s): Research Update/Product Launch
bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream

08-Apr-2025 / 10:17 CET/CEST


bonyf Advances to Phase 3 in the Development of Alginate-Organic Denture Fixative Cream

fncls.ssp?fn=download2_file&code_str=ee6ab2226a4ac74873f6b59a3d8c8088

Clinical Study Confirms Exceptional Performance and High Tolerability

Knokke-Heist (Belgium), 8 April 2025, 6:00 a.m.; bonyf NV (Mnemonic: MLBON), a leader in dental consumer goods and professional dental consumables, announces that it has successfully advanced to Phase 3 in the development of its innovative Alginate-Organic Olive-oil based Denture Fixative Cream following a positive clinical-dermatological application study conducted by Dermatest GmbH (Germany).

The study assessed the product’s efficacy and safety after daily application over five consecutive days by healthy denture wearers.

The primary objective of the study was to evaluate the retention, stability, and functional benefits of the Alginate-Organic Olive-oil based Denture Fixative Cream while also investigating its tolerability according to stringent clinical-dermatological test criteria.

The results were highly encouraging, demonstrating that Alginate-Organic Olive-oil based Denture Fixative Cream significantly improves masticatory ability and provides long-lasting retention for upper dentures, with holding times of up to 24 hours when applied according to instructions.

Additionally, the study confirmed the excellent tolerability of the product. All participants completed the five-day application period without experiencing any adverse reactions, such as irritation or allergic responses.

These findings underscore the unique positioning of bonyf’s Alginate-Organic Olive-oil based Denture Fixative Cream as a superior solution in the market—offering both extended hold performance and a healthy, organic-based formulation.

“The successful outcome of this study is a significant milestone for bonyf, as we continue our mission to develop cutting-edge solutions that enhance the well-being of denture wearers”, said CEO, Jean-Pierre Bogaert.

bonyf remains committed to innovation and plans to accelerate preparations for market launch, with Alginate-Organic Olive-oil based Denture Fixative Cream poised to set a new standard in denture care.

For more information, visit bonyf.com or contact investor@bonyf.com.

bonyf’s strengths

  • Products with patented formulations
  • Produced in Switzerland compliant with stringent international quality regulations
  • Proven clinical efficacy
  • Commercial presence in 37 countries
  • Prospects for solid growth and rapid profitability
  • A fast-growing oral and dental care market

 

fncls.ssp?fn=download2_file&code_str=88c87275d89f559171460acae79de225

About bonyf

Incorporated in 1979, bonyf specialises in the development, production and selling of cutting-edge oral & dental care products. bonyf is a forward-thinking company committed to revolutionizing oral care through innovation and research. With a focus on quality and efficacy, bonyf develops cutting-edge products designed to enhance the well-being of individuals worldwide. Through its unwavering commitment to innovation and continuous improvement, bonyf makes a real difference to people suffering from dental and oral conditions. The company has its R&D facilities in Liechtenstein (in the renown dental valley), a production plant in Switzerland and distributes its product range in 37 countries worldwide. Benefiting from seven patent protected formulations and products developed in-house, bonyf expects strong future development, driven by the fast-growing oral and dental care market.

For more information about bonyf and its innovative oral care products, please visit www.bonyf.com.

 

bonyf

Jean-Pierre Bogaert

investor@bonyf.com

fncls.ssp?fn=download2_file&code_str=c2f449a968e9dc4ef19a15ba0be90eab

 



Dissemination of a Financial Wire News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Language: English
Issuer: bonyf NV
Kalvekeetdijk 179, box 105
8300 Knokke-Heist
Belgium
Phone: +41 79 412 42 79
E-mail: president@bonyf.com
Internet: www.bonyf.com
ISIN: BE6333353298
EQS News ID: 2113236

 
End of Announcement - EQS News Service

2113236  08-Apr-2025 CET/CEST

MIC: XPAR

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.